



Docket No. 42982-C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: S. Goldin et al.  
SERIAL NO.: 09/637,222 EXAMINER: P. O'Sullivan  
FILED: August 11, 2000 GROUP: 1621  
FOR: THERAPEUTIC GUANIDINES

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS  
WASHINGTON, DC 20231

SIR:

**RESPONSE TO OFFICE ACTION**

Applicants are in receipt of the Office Action dated October 22, 2002. Applicants respond to that Office Action as follows.

The only outstanding rejection is of claims 25-27, 29-31, 32-34, 36 and 37 d under 35 U.S.C. 103 over Weber et al. (U.S. Patent 5,190,976) taken with Durant et al. (U.S. Patent 6,013,675) and Durant et al. (U.S. Patent 6,153,604). The rejection is traversed.

Applicants' claims recite guanidine compounds that include a guanidine moiety with *two* primary amino or unsubstituted imine (e.g.  $-NH_2$  or  $=NH$ ) groups.

The cited documents do not disclose such compounds. The compounds named in the cited documents have one primary amino or unsubstituted imine group of a guanidine moiety.

Such structural differences make clear that a prima facie case under Section 103 does not exist here.

In view thereof, reconsideration and withdrawal of the rejection are requested.

04/03/2003 MAHMED1 00000027 09637222

01 FC:2253

465.00 OP

RECEIVED  
APR 10 2003  
TECHNOLOGY CENTER 2800

S. Goldin et al.  
U.S.S.N. 09/637,622  
Page 2

In accordance with the Examiner's request, copies of the previously cited documents are being provided.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Respectfully submitted,



Peter F. Corless (Reg. 33,860)  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444